Ionis Pharmaceuticals Stock Price, News & Analysis (NASDAQ:IONS)

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 4 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings or view top-rated stocks.

13 Wall Street research analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their IONS share price targets range from $27.00 to $67.00. On average, they predict the company's share price to reach $48.23 in the next twelve months. This suggests that the stock has a possible downside of 3.3%.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS stock has increased by 32.1% and is now trading at $49.89.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our IONS earnings forecast.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its quarterly earnings results on Thursday, November, 2nd. The company reported ($1.03) EPS for the quarter, missing the consensus estimate of ($1.01) by $0.02. The business earned $144 million during the quarter, compared to analysts' expectations of $139.42 million. Ionis Pharmaceuticals had a negative trailing twelve-month return on equity of 90.50% and a negative net margin of 66.34%.

ETFs with the largest weight of Ionis Pharmaceuticals (NASDAQ:IONS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), Horizon Kinetics Medical ETF (MEDX), Franklin Genomic Advancements ETF (HELX), Virtus LifeSci Biotech Products ETF (BBP), Principal Healthcare Innovators ETF (BTEC) and VanEck Morningstar SMID Moat ETF (SMOT).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (14.98%), Clearbridge Investments LLC (3.37%), Tweedy Browne Co LLC (2.45%), ARK Investment Management LLC (1.65%), Wellington Management Group LLP (1.23%) and Charles Schwab Investment Management Inc. (0.87%). Insiders that own company stock include Allene M Diaz, B Lynne Parshall, Brett P Monia, Brian Birchler, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends.

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.